Botanix Pharmaceuticals Ltd Receives US Patent Allowance for Sofdra
Botanix secures US patent allowance strengthening Sofdra protection
Botanix Pharmaceuticals (ASX:BOT) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a US patent application covering the drug substance for Sofdra, its FDA-approved treatment.
The announcement, made on 13 July 2026 from Phoenix, Arizona, relates to a commercial dermatology product for the treatment of primary axillary hyperhidrosis in adults and paediatric patients aged nine and older.
Upon issuance, the patent is expected to provide additional intellectual property protection surrounding Sofdra in the United States. Importantly, this is an allowance, a step toward issuance, rather than a granted patent.
When big ASX news breaks, our subscribers know first
What the patent allowance covers
The allowed claims are directed to proprietary aspects of the sofpironium drug substance technology used in the commercial manufacture of Sofdra. Key specifics of the application include:
-
Application: Serial No. 17/611,158
-
Title: ‘Crystalline Form of Sofpironium Bromide and Preparation Method Thereof’
-
Directed to proprietary aspects of sofpironium drug substance technology utilised in the commercial manufacture of Sofdra
-
Once issued, adds to already issued patents covering Sofdra’s commercial drug substance into May 2040
For investors, the filing extends the defensive position around Botanix’s flagship commercial product in the key US market, complementing the intellectual property estate the company has already built.
Why patent protection matters for Sofdra investors
In this case, no issuance date has been disclosed.
“Drug substance” protection, in this case its crystalline form and manufacturing method, is commercially significant. For a commercial pharmaceutical company, a strong intellectual property estate can deter generic or competitor entry and support the long-term durability of product revenue. Sofdra is described as the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis, a position that patent coverage aims to defend.
The US drug substance application adds to a broader international IP campaign: Botanix also secured an EPO Intention to Grant for Sofdra covering the applicator device technology, with European protection expected to extend into May 2039 pending formal grant and country validation.
Dr Howie McKibbon, Chief Executive Officer, Botanix
“Strengthening our intellectual property estate around Sofdra remains an important strategic priority for Botanix. This Notice of Allowance further expands the Company’s US patent portfolio supporting the long-term commercial opportunity for Sofdra and reinforces our commitment to protecting key innovations associated with the product.”
The next major ASX story will hit our subscribers first
The investment takeaway
The allowance reinforces a broader thesis around Botanix: a strengthening intellectual property estate supports Sofdra’s long-term US commercial opportunity. Rather than a standalone milestone, the application adds to an existing portfolio of issued patents already protecting the commercial drug substance.
The IP estate is only one dimension of Botanix’s commercial preparation: the company is also advancing a dual-supplier strategy for Sofdra through a term sheet with Piramal, targeting a 25-40% reduction in cost of goods sold as production scales.
| Element | Detail | Investor Impact |
|---|---|---|
| Milestone | Notice of Allowance (patent not yet issued) | Signals intent to grant; extends IP runway |
| Coverage | Sofdra drug substance / crystalline form | Protects commercially critical manufacturing IP |
| Existing protection | Issued patents run into May 2040 | New application adds to this estate |
| Product status | FDA-approved, first-and-only NCE for the indication | Defensible market position |
No financial figures or timelines for issuance were disclosed in the announcement. The release was authorised by Vince Ippolito, Executive Chairman.
Don’t Miss the Next Healthcare Breakthrough
Get breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis, completely FREE. Join 20,000+ investors already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive the moment-by-moment updates that matter before the broader market reacts.